| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | 0.051 | 0.8 |